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domains: Two Z-alpha domains, three dsRNA-binding
domains and the putative deaminase domain, which are
located in exon 2, exons 2-7 and exons 9-14 respectively
[4]. The deaminase domain of the DSRAD protein is
located in the codon from 886 to 1,221, which is approxi-
mately 30% of the full length of the DSRAD protein.
These results suggest that the deaminase domain might
be a hot spot for mutations [5]. The missense mutation
c.3073A>G alters a conserved amino acid residue at 958
in exon 10, which is located in the putative deaminase
domain, so the amino acid residue at 958 is suspected to
play an important role in the conformation of the catalytic
site of the enzyme, and the mutation at this position could
probably compromises enzyme activity [6].
In conclusion, the results provide an addition to the DSH
mutation database and will contribute further to the under-
standing of DSH genotype/phenotype correlations and to
the pathogenesis of this disease. In a future study, we will
construct the p.H958R mutant of DSRAD, and explore
the pathogenesis of DSH. ■
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Hansen’s disease in an HIV patient
complicated by deep vein thrombosis:
a rare complication of thalidomide
therapy
A 33-year-old man HIV1-positive (born in Angola and a
resident of Portugal since 1997), treated with high antire-
troviral treatment (HAART) since 1999, was diagnosed
with borderline leprosy, in a type 2 reaction, and was trea-
ted with multibacillary-multidrug therapy, as defined by
the WHO, in combination with prednisolone (60 mg/
day). Three months later, thalidomide therapy (200 mg/
day) was successfully introduced to control severe and
recurrent Erythema Nodosum Leprosum (ENL). Six
weeks later, the patient developed dyspnea and severe
edema in both legs (figure 1).
Homan’s sign was positive and a doppler ultrasonography
revealed massive adherent thrombosis in both popliteal
and femoral veins, extending to the common iliac vein.
Angio-CT was consistent with pulmonary thromboembo-
lism with pulmonary infarction. A potential prothrombotic
state was excluded following analysis of erythrocyte and
platelet counts, lipidemia, proteins C and S blood levels,
search for resistance to activated protein C and antithrom-
bin III levels, lupus anticoagulant, anticardiolipin or
anti-β2-glycoprotein antibodies. Moreover, the patient
did not have any other associated thrombotic risk factors,
including cigarette smoking, infrequent or heavy hard
drug use, immobility, malignancy, heart disease, inflam-
matory bowel disease, nor a history of previous throm-
botic episodes.
Thalidomide therapy was discontinued and the patient
was treated with subcutaneous low-molecular weight hep-
arin (enoxaparin 80 mg b.i.d.) and oral warfarin. His con-
dition progressively improved and, after successful antic-
oagulation therapy, thalidomide was safely restarted and a
vena cava filter implanted. One year later the patient
remains well, medicated with MB-MDT, thalidomide
200 mg/day, warfarin and prednisolone (10 mg/day).
The first reports of thrombotic complications related to
thalidomide therapy were observed in a series of 5
patients, 4 with lupus erythematous and 1 with severe
atopic dermatitis (all with thrombotic risk factors) [1]. In
addition, thalidomide-triggered thrombosis had been
reported in patients with cicatritial pemphigoid, sarcoido-
sis or aphthosis and during the treatment of malignancy
(multiple myeloma and renal-cell carcinoma), particularly
when associated with chemotherapy [2-5]. Almost 6500
ENL patients who did not respond to other treatment
drugs have been treated with thalidomide. Among them,
DVT was reported in only two patients but neither had
Figure 1. Edema of both legs, more accentuated in the right
foot with a positive Godet sign.
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associated pulmonary thrombosis. The first patient
received concomitant dexamethasone-cyclophosphamide
pulses [4] and the second was similarly treated with pred-
nisolone [5]. In those cases DVT developed after eight
and six weeks post thalidomide therapy, respectively, but
in neither case was thalidomide restarted. Interestingly, in
our patient this drug was safely restarted two weeks later
following successful anticoagulation therapy and one year
later the patient is still being treated (with concomitant
corticosteroids) without further complications. In retro-
spect, we recognize that it was possible in our patient
that corticotherapy and HIV infection contributed to
thrombosis development. In fact, Vetrichevel et al.
recently suggested that there was a possibility of thrombo-
sis in patients receiving thalidomide therapy together with
corticosteroids i.e., both drugs have a synergistic, suppres-
sive effect on thrombomodulin because they inhibit/
decrease the production of TNF-α [5]. Currently available
epidemiological evidence also suggests that chronic HIV
infection is associated with a two- to ten-fold increased
risk of venous thrombosis in comparison to an age-
matched control population [6]. The hypercoagulable
state present in many HIV patients is associated with an
increased risk of haemostatic changes and of superim-
posed infections. HAART has also been associated with
an amplified risk of DVT by some investigators, however,
the data are insufficient to support these claims [6].
This case highlights the increased thrombosis risk follow-
ing thalidomide therapy in an HIV/leprosy co-infected
patient without major thrombotic risk factors, even when
used as an indicated treatment for ENL, and highlights the
possible danger of not diagnosing DVT in an ENL patient
since edema of both legs is a common occurrence during
this reaction. ■
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Tocilizumab is a humanized anti-human interleukin 6
receptor (IL-6R) antibody, engineered by grafting the
complementarily determining regions of a mouse anti-
human IL-6R antibody into human IgG1 to create a
human antibody with a human IL-6R binding site [1, 2].
Tocilizumab binds to the IL-6 binding site of human IL-
6R and competitively inhibits IL-6 signaling. A series of
clinical studies have shown that inhibition of IL-6 signal-
ing by tocilizumab is therapeutically effective in Castle-
man disease and rheumatoid arthritis (RA). In Japan, toci-
lizumab began to be widely used for patients with
Castleman disease and RA refractory to other therapies
in 2005 and 2008, respectively. We report a 62-year-old
Japanese woman who developed erythroderma after
administration of tocilizumab for her RA.
Twenty four years before our first examination, the patient
was diagnosed as having RA because of multiple arthral-
gia. Although she took oral non-steroidal anti-
inflammatory drugs (NSAID), oral corticosteroid and
methotrexate, the arthralgia gradually worsened. She was
referred to our hospital for further treatment of RA. The
patient began to receive an intravenous injection of toci-
lizumab, 280 mg (8 mg/kg) once per month. Two days
after the first injection, the patient noticed a slight ery-
thematous eruption on her face, which subsided in a few
days. One day after the second injection, she again devel-
oped erythema on the face to chest, although, it disap-
peared in a few days without any treatment. A few
hours after the third injection of tocilizumab, generalized
erythema developed on the whole body with severe itch
(figure 1). There was no oral exanthema. A peripheral
blood sample showed a normal leukocyte count of 4800/
μL (Normal: 3500-9500) with 15.9% eosinophils (763/
μL). The serum levels of hepatic enzymes were within
normal ranges. She had neither a high fever nor lymph
node swelling, suggesting that she did not suffer from
viral infection. We could not obtain her informed consent
for a skin biopsy. Since the eruption and eosinophilia
occurred in accordance with the drug injection, we diag-
nosed her erythroderma as a skin eruption due to tocilizu-
mab. Since we could not obtain her informed consent for
further examinations, we did not perform skin patch test-
ing or lymphocyte stimulation tests. The administration of
tocilizumab was discontinued and the erythroderma sub-
sided in a week with topical betamethasone butyrate pro-
pionate alone.
Tocilizumab inhibits the signaling of IL-6, an important
inflammation moderator. Several kinds of serious adverse
events due to tocilizumab have been reviewed by Nishi-
moto N et al. [3]. Infections such as pneumonia, herpes
zoster, acute bronchitis and pyelonephritis are the most
frequently observed side effects. However, aside from her-
pes zoster, only one case of cutaneous adverse effects of
tocilizumab has been reported in the English literature [4].
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